BioSpace News Archive

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder: A Double-Blind, Randomized, Sham-Controlled Pilot Study in the journal, Brain Stimulation.

Ovid Therapeutics Inc. announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York, New York on Monday, September 12, 2022, at 12:00 p.m. ET.

AbbVie will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022.

Curis, Inc. announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 4:00 p.m. ET in New York, NY.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 10 new employees.

Spine BioPharma, Inc., a company committed to developing non-opiate, non-surgical therapies for the treatment of Chronic Low Back Pain (CLBP) and related disability caused by Degenerative Disc Disease (DDD), today announced the first patient treated in a Phase 3 clinical study of SB-01 For Injection (SB-01).

PTC Therapeutics, Inc. announced the four recipients of its 2022 STRIVE Awards for Duchenne Muscular Dystrophy.

Clario, a technology company that delivers the leading endpoint solutions for decentralized, hybrid and site-based clinical trials, announced that Otis Johnson, Ph.D., Chief Diversity, Inclusion and Sustainability Officer, has been named one of PharmaVoice’s 100 most inspiring individuals in the life-sciences industry.

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced a clinical supply agreement with Regeneron for PD-1 inhibitor Libtayo® (cemiplimab).

Amyris, Inc. announced that management will participate in fireside chats moderated by equity research analysts, and provide updates, at two upcoming investor conferences.